~~<i id='6D8A416F97'><strike id='6D8A416F97'><tt id='6D8A416F97'><pre id='6D8A416F97'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：entertainment 2025-09-28 22:42:16 Page View：8125

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What’s missing from the debate over nursing home staff minimums
Next article： How one medical school became remarkably diverse

explore

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Readout Newsletter: Amgen, Regeneron, BGI Group and more

KristofferTripplaar/SipaviaAPWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup toget

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Adopting new red light myopia treatments may be short

AdobeMyopia,ornear-sightedness,isontherise:Nearlyhalfoftheworld’spopulationwillbenearsightedby2050,